Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.Wendy Osborne, Kirit M. Ardeshna, Peter A. McSweeney et al.|Journal of Clinical Oncology|2020Cited by 45
Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failureNitya Nathwani, Robert W. Chen, Amrita Krishnan et al.|Leukemia & lymphoma/Leukemia and lymphoma|2012Cited by 28
Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCTRobert W. Chen, Stephen J. Forman, Joycelynne Palmer et al.|Blood|2014Cited by 14
Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 StudyAriela Noy, Robert W. Chen, Sven de Vos et al.|Blood|2016Cited by 10
Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 StudyNathan Fowler, M. Lia Palomba, Loretta J. Nastoupil et al.|Blood|2016Cited by 9